What oral glucocorticoid regimen is recommended for a rheumatoid arthritis flare in a patient already taking Rinvoq (upadacitinib)?

Oral Glucocorticoid Regimen for RA Flare in Patients on Rinvoq

For a rheumatoid arthritis flare in a patient already taking Rinvoq (upadacitinib), use a short course of oral prednisone at 0.3-0.5 mg/kg/day (typically 15-30 mg daily) for 1-2 weeks, then taper rapidly over 4-8 weeks to discontinuation. 1, 2

Dosing Strategy

Initial dose for flare management:

• Use oral prednisone 0.3-0.5 mg/kg/day (maximum ~30 mg/day) for polyarticular flares 1, 2
• Continue for 1-2 weeks at this dose 1, 2
• Administer as a single daily dose rather than divided doses 3

Tapering approach:

• After initial 1-2 weeks, taper to 10 mg/day prednisone equivalent within 4-8 weeks 3
• Once at 10 mg/day, reduce by 1 mg every 4 weeks until discontinuation 3
• Total duration should be less than 3 months 4, 5, 4

Critical Considerations

Avoid chronic glucocorticoid use:

• Strongly avoid adding chronic low-dose glucocorticoids regardless of disease activity 4, 5, 4
• The known adverse effects (weight gain, osteoporosis, cataracts, cardiovascular events) outweigh benefits when used chronically 4, 5, 4
• If flares are recurrent, escalate the Rinvoq dose or add/switch DMARDs rather than maintaining chronic steroids 4

Rinvoq continuation:

• Continue Rinvoq at current dose during the flare and steroid course 6
• Do not withhold upadacitinib during acute flare management 6
• The perioperative guideline confirms continuing current glucocorticoid doses in patients on JAK inhibitors like upadacitinib 6

Alternative Approaches

Intra-articular injections preferred when appropriate:

• If only a few joints are involved, consider intra-articular triamcinolone hexacetonide instead of systemic steroids 4, 5, 4
• Triamcinolone hexacetonide is strongly preferred over triamcinolone acetonide for longer duration of response 4, 5, 4
• This approach avoids systemic glucocorticoid exposure and associated adverse effects 4, 5, 4

Intramuscular methylprednisolone:

• Consider 120 mg IM methylprednisolone every 3 weeks as an alternative to oral glucocorticoids 3
• This may improve adherence and reduce daily pill burden 3

Safety Monitoring

Monitor for glucocorticoid-related adverse effects:

• Assess for diabetes, hypertension, osteoporosis, glaucoma, and weight gain 3
• Document risk factors for steroid-related complications before initiating therapy 3
• Patients with comorbidities (diabetes, osteoporosis, glaucoma) should receive lower initial doses within the recommended range 3

Upadacitinib safety considerations:

• Be aware that herpes zoster rates are higher with upadacitinib compared to other therapies 7, 8, 9
• Serious infection rates with upadacitinib range from 2.62-4.6 events per 100 patient-years across indications 8
• Adding systemic glucocorticoids may further increase infection risk, reinforcing the need for short-term use only 8

Common Pitfalls

Avoid these errors:

• Do not use initial prednisone doses >30 mg/day for RA flares 3
• Do not use initial doses ≤7.5 mg/day as they are inadequate for acute flare management 3
• Do not continue glucocorticoids beyond 3 months without reassessing the underlying treatment strategy 4, 5, 4
• Do not use supraphysiologic "stress doses" of glucocorticoids—continue the current therapeutic dose 6

When to escalate therapy instead:

• If the patient requires repeated courses of glucocorticoids for flares, this indicates inadequate disease control 4
• Consider increasing upadacitinib from 15 mg to 30 mg daily if tolerated, or adding/switching conventional DMARDs 10
• Chronic low-dose glucocorticoids should not be used as a substitute for optimizing disease-modifying therapy 4, 10